Phase 4
Completed N=60
Study Comparing Prandial Insulin Aspart vs. Technosphere Insulin in Patients With Type 1 Diabetes on Multiple Daily Injections: Investigator-Initiated A Real-life Pilot Study-STAT Study
Diabetes Mellitus, Type 1
Source: ClinicalTrials.gov NCT03143816 ↗
Enrolled (actual)
60
Serious AEs
0.0%
Results posted
Feb 2022
Primary outcomePrimary: Change in Time in Range (%) (70-180 mg/dl) With TI on CGM — 53.5; 58.4 percent time in range
◆ Published Evidence
Established
67citations · ~8 / year
Improved Postprandial Glucose with Inhaled Technosphere Insulin Compared with Insulin Aspart in Patients with Type 1 Diabetes on Multiple Daily Injections: The STAT Study.
Summary
This is an investigator-initiated, prospective, randomized, multicenter, parallel, open-label, pilot clinical trial evaluating the efficacy of TI for PPBG, PPGE, and time-in-range on CGM download in patients with T1D. TI is an inhaled ultra-rapid-acting insulin, approved by the FDA for use in patients with diabetes. This is a pilot, real-life study where patients will continue their routine diabetes care and use post-meal correction dosages as deemed necessary for normalizing PPBG as per the protocol.
This multi-center study will enroll 60 patients with T1D, A1c values between 6.5 to 10%. The patients will be randomized in 1:1 fashion to either TI or NL. Patients who are randomized into the NL arm will continue using their usual prandial insulin dose before meals. Patients who are randomized into the TI arm will be instructed to dose before the meals and take necessary corrections at 1- and 2-hours after meals to optimize PPBG (Table 1B). There will be a total of 7 study visits (screening visit, randomization visit, 2 clinic, and 3 phone visits). There will be a 4-week treatment comparison between TI and NL and 1-week of post-study follow up. (Phone visit; Figure-1). Standard lab tests (A1c, complete metabolic panel {CMP}, complete blood count {CBC}) will be performed at the screening visit.
All patients will use real-time CGM (Dexcom G5®, San Diego, CA), which will be provided at the randomization visit for their day-to-day diabetes care. CGM data will be downloaded at every clinic visit on a secured computer. The data will be analyzed after the study for different primary and secondary end points. All patients will be allowed to keep the CGM after the study is over for their day-to-day diabetes care.
Linked Publications
-
Improved Postprandial Glucose with Inhaled Technosphere Insulin Compared with Insulin Aspart in Patients with Type 1 Diabetes on Multiple Daily Injections: The STAT Study.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Time in Range (%) (70-180 mg/dl) With TI on CGM |
53.5; 58.4 | — |
| SECONDARY Change in Post-prandial Glucose Excursion (mg/dl) (1-4 Hours After Meals) With TI |
45; 60 | — |
| SECONDARY Change in Glucose Variability (GV) (mg/dl) (Standard Deviation and/or Coefficient Variation) |
57.8; 66.3 | — |
| SECONDARY The Area Under the Curve Calculation (AUC) (Min*mg/dl) in the PPBG and PPGE, |
15020; 20020 | — |
| SECONDARY Change in HbA1c (%) in One-month Treatment |
0.25; 0.02 | — |
| SECONDARY Change in Above the Target Time (%) (>180 mg/dl) on CGM |
38.1; 41.2 | — |
| SECONDARY Hypoglycemia Frequency (%) (Below the Target <70mg/dl) on CGM |
2.2; 4.0 | — |
Eligibility Criteria
Inclusion Criteria
- Signed informed consent before any study-related activities,
- Male or female aged 18-70 years,
- Type 1 diabetes mellitus (T1D) duration more than six months
- Treatment with multiple daily injections (MDI) for at least three months before screening visit; stable insulin dose for the last one month,
- No use of any oral anti-diabetics, any other form of insulin other than mentioned in the protocol, or any other type of injections such as glucagon-like-peptide-1 (GLP-1) analogs, pramlintide or insulin/GLP-1 analog combinations,
- A1c between 6.5 to 10%,
- Willingness to routinely collect at least two blood glucose measurements per day needed to calibrate the CGM. Beyond the calibrations, patients may use CGM for necessary action without having to confirm with fingersticks self-monitoring blood glucose (SMBG), as approved by the Food and Drug Administration (FDA),
- BMI ≤35 kg/m2,
- Ability and willingness to adhere to the protocol including clinical and phone visits and 4-week-long CGM wear,
- Using insulin glargine or insulin degludec as basal insulin,
- Able to use and understand CGM data,
- Willing to complete phone and clinic visits,
- Patients who eat three main meals in a day (breakfast, lunch, and dinner),
- Patients who use insulin-carb ratio for bolus,
- Ability to speak, read, and write English, and
- Patients prandial insulin need must be 2.0 mg/dl or a calculated creatinine clearance of <50 mL/min,
- Advanced or unstable retinopathy needing laser procedure or vitrectomy,
- History of pancreatitis,
- Extensive skin changes/diseases that inhibit wearing a sensor on normal skin,
- Known allergy to adhesives,
- Known allergy to study medication,
- Participation in another investigational study protocol within 30 days before enrollment,
- Known chronic obstructive pulmonary disease, pulmonary hypertension, asthma, pulmonary fibrosis, or any chronic pulmonary infection, or any systemic disease that primarily affects the lungs. History of any pulmonary nodule will be excluded to participate in the study,
- Active smokers,
- Marijuana users,
- Insulin pump users,
- Using insulin detemir or NPH as basal insulin, and
- Any other condition, as determined by the investigator, which could make the subject unsuitable for the trial, impairs the subject's suitability for the trial, or impairs the validity of the informed consent -
Data sourced from ClinicalTrials.gov (NCT03143816) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.